Clinical Trial Update: Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone [Phase 4]

View source ↗

Summary

Phase 4 study update shows completion and posted results for the efficacy and safety of Sodium Zirconium Cyclosilicate (SZC) in managing hyperkalemia in symptom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction
• Hyperkalemia

Drugs mentioned

• Lokelma (sodium zirconium cyclosilicate)

Snippet

Sponsor: AstraZeneca | Conditions: Hyperkalaemia, Heart Failure With Reduced Ejection Fraction | Phase 4 | Status: COMPLETED | Results posted: 2025-07-09